<DOC>
	<DOCNO>NCT02836977</DOCNO>
	<brief_summary>Primary Objective : To compare 3-year disease free survival ( DFS ) tegafur-uracil follow adjuvant oxaliplatin-based regimen observation follow adjuvant oxaliplatin-based regimen patient stage III colon cancer radical resection . Secondary Objectives : - To assess 5-year overall survival ( OS ) arm - To assess safety profile</brief_summary>
	<brief_title>Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen Patients With Stage III Colon Cancer After Radical Resection</brief_title>
	<detailed_description>Objectives : 1 . Primary Objective : To compare 3-year disease free survival ( DFS ) tegafur-uracil follow adjuvant oxaliplatin-based regimen observation follow adjuvant oxaliplatin-based regimen patient stage III colon cancer radical resection . 2 . Secondary Objectives : - To assess 5-year overall survival ( OS ) arm - To assess safety profile Patient Selection Enrollment : Number Subjects : Eligible patient randomize 2 arm ratio 2:1 , reach approximately 546 patient total . Plan Study : 1 . Study Design This open-label , randomize , comparative , double arm , multicenter study assess disease free survival , overall survival , safety profile tegafur-uracil follow adjuvant oxaliplatin-based regimen maintenance one-year patient stage III colon cancer radical resection Taiwan . 2 . Subject Number Eligible patient randomize 2 arm ratio 2:1 , reach approximately 546 patient total . 3 . Study Schedule Study date : time get approval letter issue regulatory authority institutional review board ( IRB ) Expected recruitment rate : 23 subjects/month Duration recruitment : least 2 year . Duration study : least 5 year . 4 . Visit Schedule The schedule assessment ( please refer section 8.4 detail ) indicate number timing plan visit , must maintain accurately possible . The visit schedule must maintain accurate possible . 5 . Duration Treatment Treatment administer maximum one year , disease progression , intolerable toxicity , consent withdrawal time study , patient withdraw .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>To eligible inclusion , subject must fulfill follow criterion : 1. pathologically confirm colon carcinoma ; 2. stage III disease ( T14 , N12 , M0 define AJCC 7th Edi . ) ; 3. completion adjuvant oxaliplatinbased regimen without evidence recurrent disease ; 4. entry trial within 3 week adjuvant oxaliplatinbased regimen ; 5. performance status ECOG 0 , 1 , 2 ; 6. age 20 80 year old ; 7. write informed consent participate trial . Patients fulfill follow criterion exclude trial : 1. previous current systemic malignancy exception curatively treat nonmelanoma skin cancer cervical carcinoma situ , unless diseasefree interval least 5 year ; 2. inadequate hematopoietic function define : 1. hemoglobin &lt; 9 g/dL ; 2. absolute neutrophil count ( ANC ) &lt; 1,500/mm3 ; 3. platelet count &lt; 100,000/mm3 ; 3. inadequate organ function define : 1. total bilirubin &gt; 2 time upper limit normal ( ULN ) ; 2. hepatic transaminase ( ALT AST ) &gt; 2.5 x ULN ; 3. creatinine &gt; 1.5 x ULN ; 4. significant medical condition contraindicate tegafururacil render patient high risk treatment complication base investigator 's discretion ; 5. presence serious concomitant illness ; 6. participation another clinical trial investigational drug within 30 day prior entry ; 7. pregnant lactate woman woman childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>tegafur-uracil</keyword>
</DOC>